SCHIZOPHRENIA. Schizophrenia
Conditions
Interventions
Intervention 1: Intervention group: Patients with schizophrenia who receive a dose of 2000 IU Vitamin D(Prepared by Dana Pharmaceuticals Inc.) per day(after lunch). Intervention 2: Control group:Schiz
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: People with schizophrenia admitted to Razi Hospital The age range of 18-65 years old in men and the age range of 18-50 years in women Diagnosis of schizophrenia based on the DSM-V (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) and Psychiatrist's Confirmation PANSS score above 70 Did not receive any dietary supplements ( oral or injectable) in the past year(such as vitamin D3 and calcium) Serum levels of the vitamin D3 below 20 ng / ml The desire to participate in the study
Exclusion criteria
Exclusion criteria: Pregnancy or breastfeeding comorbididty with other major psychological or neurological diseases such as bipolar disorder and multiple sclerosis Smoking and alcohol consumption History of compliance with certain diets Use of serum vitamin D suppressants (such as anticonvulsants and glucocorticoids)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Components of metabolic syndrome including waist circumference, fasting blood glucose, HDL, triglyceride and blood pressure. Timepoint: Before the intervention and 8 weeks later. Method of measurement: Accordingly, the bandwidth (waist circumference), kit and autoanalyser (sugar, HDL and triglyceride) and mercury pressure gauge (blood pressure). | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum levels of glycogen synthase kinase 3, beta-catenin, BDNF, S100B and ZAG. Timepoint: Before the intervention and 8 weeks later. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParinaz Kalejahi
Tabriz University of Medical Sciences
Outcome results
None listed